Monoclonal Antibodies

If you test positive for COVID-19 and meet the following criteria, you may be eligible to receive a monoclonal antibodies infusion:

  • Your COVID-19 test comes back positive
  • You are not hospitalized
  • You are less than 10 days since onset of mild to moderate symptoms
  • You have high-risk factors that include:
    • 65 years old
    • Obesity with Body Mass Index >35 (adults)
    • Diabetes
    • Chronic kidney disease
    • Immunosuppressive disease, or on immunosuppressive therapy>55 years old AND have § Cardiovascular disease, OR Hypertension, OR Chronic obstructive pulmonary disease / other chronic respiratory disease

What are monoclonal antibodies?

  • Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful viruses and bacteria that can cause disease
  • Bamlanivimab (Lilly) and casirivimab/imdevimab (Regeneron) are monoclonal antibodies that the U.S. Food and Drug Administration (FDA) has issued an emergency use authorization for the treatment of mild-to-moderate COVID-19 in non-hospitalized adult and pediatric patients 

Why would I consider receiving a monoclonal antibodies infusion?

  • An infusion may minimize the potential for higher risk patients to progress to severe disease and/or hospitalization